NICE nixes AstraZeneca's Lynparza; Faes sets China marketing deal; Sanofi faces ERISA suit over alleged kickbacks;

> England's cost-effectiveness gatekeepers at the National Institute for Health and Care Excellence rejected AstraZeneca's ($AZN) new ovarian cancer drug Lynparza in preliminary guidance, saying it costs too much for the benefits it provides. Release | Report

> Spain's Faes Farma inked a deal with Chinese drugmaker Eddingpharma on a joint venture that will market products in China, beginning with four of Faes' drugs. Report

> A combo of two Genentech drugs, Perjeta and Herceptin, helped breast cancer patients live longer without their disease recurring compared with Herceptin plus chemo. Story

> Stockholders in Sanofi's ($SNY) group savings plan allege that the plan's administrators violated retirement plan laws by providing misledaing information about the company's alleged kickbacks to doctors, subject of a whistleblower lawsuit. Report

And Finally... Doctors are growing increasingly impatient with cancer drug shortages. Report